Research article · 19 Aug 2025
Conference abstractPublished 3 Jul 2017
Novel Nitroimidazoles with promising anti-tubercular activity: Optimizing ADME/Tox properties to increase drug discovery success
Indian Institute of Integrative Medicine-CSIR, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
New compounds against tuberculosis are urgently needed to combat the crisis of drug resistance in tuberculosis (TB). We have identified a nitro-dihydro-imidazooxazole analog, IIIM-114 as a new anti-tubercular agent with a MIC of 0.06 Ã?¼g/ml against H37Rv. The structural properties of the compound were studied using Schrodinger Software. Since, IIIM-017 followed Lipinski’s and Verber’s rule, based on these properties was chosen for further investigation. A rapid and sensitive liquid chromatography (LC) coupled to tandem mass spectrometry (MS-MS) and electrospray ionization (ESI) method was developed and validated for the quantification of IIIM-114 in mice plasma. The chromatographic separation was accomplished using a gradient mode and the mobile phase comprised of acetonitrile and 0.1% formic acid in water. The flow rate used was 0.6 ml/min on a C18e high performance Chromolith column. The MS-MS ion transitions used were 467>227.0, 467>338. The entire study was validated for accuracy, precision, linearity, range, selectivity, LLOQ, recovery and matrix effect in accordance with the FDA guidelines of method validation. The method was applied successfully to determine solubility, lipophilicity, microsomal stability and PK. Lipophilicity was determined experimentally as Octanol-PBS partition coefficient (log P) and the compound exhibited a log P of -0.08. The method was also applied successfully in determining microsomal stability wherein the compound was found to be very slightly metabolized by RLM. The pharmacokinetics was performed on male Balb/c mice at 5 mg/kg (p.o) and exhibited acceptable in-vivo pharmacokinetic parameters. Thus, IIIM based on acceptable drug-like properties should undergo further investigation.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Drug Designing: Open Access.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Gurleen Kour”
